



an Open Access Journal by MDPI

Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer

Guest Editors:

Dr. Prema Robinson

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Dr. Miguel Muñoz

1. Pediatric Intensive Care United, Virgen del Rocio University Hospital, 41013 Seville, Spain
2. Research Laboratory on Neuropeptides (IBIS), Virgen del Rocio University Hospital, 41013 Seville, Spain

Deadline for manuscript submissions:

closed (15 June 2023)

Message from the Guest Editors

Dear Colleagues,

This Special Issue will highlight target therapies and targetable molecules that could be availed for treatment of Cancer.

The predominant features of cancer include dysregulated cellular proliferation, cell death, immunosuppressive factors, anti-cancer immune responses and angiogenesis leading to growth, invasion and metastases. Diseases that could predispose to cancer include but are not limited to Lynch syndrome, Li-Fraumeni syndrome, human papillomavirus (HPV) infection, Epstein-Barr virus (EBV) infection, Helicobacter pylori infection, *Opisthorchis viverrini* infection, Schistosomiasis, chronic diabetes, pancreatitis, ulcerative colitis and Crohn's disease.

Targeted cancer therapies/targetable molecules include but not limited to hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules.

Targetable molecules include but not limited to transcription factors, signal transduction molecules, peptides, kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and proteasomes.



mdpi.com/si/119967

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)